Product Information
CLONAZEPAM 1 MG ODT is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5669 per EA under NDC 00093929367. Its NADAC has been published 223 times since Jun 29, 2022.
FDA first approved this application on Aug 10, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093929367
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLONAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA077194FDA Approved
8/10/2005
TE Code
AB
On Market Since
11/22/2021
Pharmacological Classes
Price Statistics
The NADAC for CLONAZEPAM 1 MG ODT has been published 223 times since Jun 29, 2022, and over the history we have for it it has declined 24.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5669 per EA |
|---|---|
| All-time high | $0.8268 (Nov 16, 2022) |
| All-time low | $0.4241 (Mar 22, 2023) |
| 52-week high | $0.5921 |
| 52-week low | $0.4879 |
| Median price | $0.5803 |
| Average price | $0.5912 |
| Largest weekly change | +48.7% (Jun 19, 2024) |
| Weeks tracked | 223 |
| Tracking since | Jun 29, 2022 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 96% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clonazepam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLONAZEPAM 1 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for CLONAZEPAM 1 MG ODT, manufactured by Teva Pharmaceuticals USA Inc., is $0.5669 per EA (NDC 00093929367), effective Sep 30, 2026.
How has the price of CLONAZEPAM 1 MG ODT changed over time?
Over the history we have for it, the NADAC for CLONAZEPAM 1 MG ODT has declined 24.5%. It has been tracked across 223 weekly CMS publications since Jun 29, 2022.
What are the highest and lowest recorded NADAC prices for CLONAZEPAM 1 MG ODT?
Since Jun 29, 2022, the NADAC for CLONAZEPAM 1 MG ODT has ranged from a low of $0.4241 (Mar 22, 2023) to a high of $0.8268 (Nov 16, 2022), with a median of $0.5803 per EA.
Are there cheaper alternatives to CLONAZEPAM 1 MG ODT?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLONAZEPAM 1 MG TABLET, is $0.0244 per EA — about 96% below CLONAZEPAM 1 MG ODT.
Who manufactures CLONAZEPAM 1 MG ODT?
CLONAZEPAM 1 MG ODT (NDC 00093929367) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.